A phase dose escalation trial of CEA-targeting CAR-T cells in patients with metastatic CEA-positive CRC reported tumour shrinkage in two of the ten patients who received the CAR-T cells with another seven patients achieving stable disease that for two patients were sustained for over 30 weeks [33]. This evidence concerns the gene CEACAM5 and neoplasm.